Check-Cap Ltd. (MBAI)vsMerck & Company Inc (MRK)
MBAI
Check-Cap Ltd.
$1.06
-0.93%
HEALTHCARE · Cap: $8.27M
MRK
Merck & Company Inc
$130.21
+0.32%
HEALTHCARE · Cap: $307.25B
Smart Verdict
WallStSmart Research — data-driven comparison
MRK leads profitability with a 13.6% profit margin vs 0.0%. MBAI trades at a lower P/E of 1.6x. MRK earns a higher WallStSmart Score of 50/100 (D+).
MBAI
Avoid31
out of 100
Grade: F
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MBAI.
Margin of Safety
-62.3%
Fair Value
$81.23
Current Price
$130.21
$48.98 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 120 in profit
Conservative balance sheet, low leverage
Reasonable price relative to book value
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MBAI
The strongest argument for MBAI centers on P/E Ratio, Return on Equity, Debt/Equity.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : MBAI
The primary concerns for MBAI are Revenue Growth, EPS Growth, Market Cap.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
MBAI carries more volatility with a beta of 0.79 — expect wider price swings.
MRK is growing revenue faster at 4.9% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (50/100 vs 31/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Check-Cap Ltd.
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Check-Cap Ltd., a clinical stage medical diagnostics company, focuses on capsule-based screening technology products. The company is headquartered in Isfiya, Israel.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?